Clinical Trial Detail

NCT ID NCT04044859
Title Surpass: ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Tumors
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Adaptimmune
Indications

myxoid liposarcoma

esophageal cancer

gastroesophageal junction adenocarcinoma

transitional cell carcinoma

head and neck cancer

synovial sarcoma

ovarian cancer

stomach cancer

melanoma

lung non-small cell carcinoma

Therapies

ADP-A2M4 cells

Age Groups: adult senior

No variant requirements are available.